MX2023012465A - Regimen de dosificacion de anti-ifnar1 para inyeccion subcutanea. - Google Patents

Regimen de dosificacion de anti-ifnar1 para inyeccion subcutanea.

Info

Publication number
MX2023012465A
MX2023012465A MX2023012465A MX2023012465A MX2023012465A MX 2023012465 A MX2023012465 A MX 2023012465A MX 2023012465 A MX2023012465 A MX 2023012465A MX 2023012465 A MX2023012465 A MX 2023012465A MX 2023012465 A MX2023012465 A MX 2023012465A
Authority
MX
Mexico
Prior art keywords
ifnar1
subcutaneous injection
dosing regime
type
disclosure relates
Prior art date
Application number
MX2023012465A
Other languages
English (en)
Spanish (es)
Inventor
Lorin Roskos
Catharina Lindholm
Yen Lin Chia
Rajendra Tummala
Joachim Almquist
Tomas Rouse
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=81750490&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2023012465(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of MX2023012465A publication Critical patent/MX2023012465A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Dermatology (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Endocrinology (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Devices For Medical Bathing And Washing (AREA)
  • Infusion, Injection, And Reservoir Apparatuses (AREA)
MX2023012465A 2021-04-23 2022-04-21 Regimen de dosificacion de anti-ifnar1 para inyeccion subcutanea. MX2023012465A (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US202163178739P 2021-04-23 2021-04-23
US202163245285P 2021-09-17 2021-09-17
US202163272851P 2021-10-28 2021-10-28
PCT/EP2022/060592 WO2022223714A1 (en) 2021-04-23 2022-04-21 Anti-ifnar1 dosing regime for subcutaneous injection

Publications (1)

Publication Number Publication Date
MX2023012465A true MX2023012465A (es) 2024-04-04

Family

ID=81750490

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2023012465A MX2023012465A (es) 2021-04-23 2022-04-21 Regimen de dosificacion de anti-ifnar1 para inyeccion subcutanea.

Country Status (25)

Country Link
US (4) US20220340669A1 (enExample)
EP (2) EP4306541A3 (enExample)
JP (2) JP7484027B2 (enExample)
KR (2) KR20250092298A (enExample)
CN (2) CN120392997A (enExample)
AU (2) AU2022260531B2 (enExample)
BR (1) BR112023021761A2 (enExample)
CA (1) CA3216387A1 (enExample)
CL (1) CL2023003114A1 (enExample)
CO (1) CO2023015498A2 (enExample)
DK (1) DK4114465T5 (enExample)
ES (1) ES2963757T3 (enExample)
FI (1) FI4114465T3 (enExample)
HR (1) HRP20231255T1 (enExample)
HU (1) HUE063562T2 (enExample)
IL (1) IL307748A (enExample)
LT (1) LT4114465T (enExample)
MX (1) MX2023012465A (enExample)
PL (1) PL4114465T3 (enExample)
PT (1) PT4114465T (enExample)
RS (1) RS64821B1 (enExample)
SI (1) SI4114465T1 (enExample)
SM (1) SMT202300382T1 (enExample)
TW (1) TW202317182A (enExample)
WO (1) WO2022223714A1 (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1781705B1 (en) * 2004-06-21 2014-10-08 Medarex, L.L.C. Interferon alpha receptor i antibodies and their uses
US20250002590A1 (en) * 2021-04-23 2025-01-02 Astrazeneca Ab Treatment of lupus nephritis with anti-type i inf receptor antibody anifrolumab
LT4114465T (lt) 2021-04-23 2023-11-10 Astrazeneca Ab Anti-ifnar1 dozavimo režimas, skirtas poodinei injekcijai
CN113621063A (zh) * 2021-08-02 2021-11-09 江苏荃信生物医药有限公司 降低单克隆抗体生产中宿主细胞蛋白含量的亲和纯化方法
CN121127499A (zh) 2023-05-19 2025-12-12 阿斯利康(瑞典)有限公司 狼疮的治疗
WO2025022280A1 (en) 2023-07-21 2025-01-30 Astrazeneca Ab Treatment of neurodegenerative diseases
GB202315831D0 (en) 2023-10-16 2023-11-29 Astrazeneca Ab Treatment of skin disease
GB202402824D0 (en) 2024-02-28 2024-04-10 Astrazeneca Ab Treatment of chronic kidney disease

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2002250236A1 (en) 2001-03-02 2002-09-19 Medimmune, Inc. Cd2 antagonists for treatment of autoimmune or inflammatory disease
US20040037809A1 (en) 2002-06-28 2004-02-26 Nastech Pharmaceutical Company Inc. Compositions and methods for enhanced mucosal delivery of interferon beta
DK1711207T3 (da) 2003-12-10 2013-03-11 Medarex Inc Interferon-alpha-antistoffer og anvendelse heraf
EP1781705B1 (en) * 2004-06-21 2014-10-08 Medarex, L.L.C. Interferon alpha receptor i antibodies and their uses
WO2006138275A2 (en) 2005-06-13 2006-12-28 The Regents Of The University Of Michigan Compositions and methods for treating and diagnosing cancer
WO2008093166A2 (en) 2006-05-11 2008-08-07 Ghent University Sialoadhesin-related compositions and methods
WO2008070135A2 (en) 2006-12-06 2008-06-12 Medimmune, Llc. Methods of treating systemic lupus erythematosus
ES2542836T3 (es) 2007-07-12 2015-08-12 The Brigham And Women's Hospital, Inc. Composiciones y métodos para diagnosticar y evaluar miopatías inflamatorias
CN101909444B (zh) 2007-11-05 2013-09-18 米迪缪尼有限公司 硬皮病治疗方法
HUE028958T2 (en) 2008-02-08 2017-01-30 Medimmune Llc Anti-ifnar1 antibodies with reduced fc ligand affinity
US20110287022A1 (en) 2008-06-20 2011-11-24 Medlmmune, Llc Interferon alpha-induced pharmacodynamic markers
BRPI0917871A2 (pt) 2008-08-15 2017-06-20 Merrimack Pharmaceuticals Inc agente terapêutico anti-erbb3 para uso em terapia de um tumor, métodos para predizer responsividade de um tumor de um agente terapêutco anti-erbb3, para selecionar terapia anti-erbb3 para um paciente, para predizer a resposta de células ao tratamento com um agente terapêutico, para identificar um biomarcador, e para evitar administração de uma droga para câncer anti-erbb3, e, kit para predizer a resposta das células ao tratamento com um agente terapêutico
ES2613055T3 (es) 2009-09-03 2017-05-22 Medimmune, Llc Diagnóstico de interferón de tipo 1
US9493570B2 (en) * 2012-06-13 2016-11-15 Medimmune, Llc Fixed dosage regimens for anti-type I interferon receptor (IFNAR) antibodies
RS64263B1 (sr) * 2015-08-19 2023-07-31 Astrazeneca Ab Stabilna anti-ifnar1 formulacija
CN106243226B (zh) 2016-08-05 2019-02-12 北京智仁美博生物科技有限公司 抗人ifnar1的抗体及其用途
US11059897B2 (en) * 2018-09-18 2021-07-13 I-Mab Biopharma Us Limited Anti-IFNAR1 antibodies for treating autoimmune diseases
KR20210131354A (ko) * 2019-02-15 2021-11-02 아스트라제네카 아베 I형 인터페론-매개 장애
KR102766960B1 (ko) 2019-11-11 2025-02-11 아스트라제네카 아베 전신성 홍반성 루푸스에서 i형 인터페론 억제
AU2021279277A1 (en) 2020-05-29 2023-02-02 Astrazeneca Ab Treatment of cardiometabolic disease with inhibitors of type I interferon signalling
TW202237647A (zh) 2020-10-08 2022-10-01 瑞典商阿斯特捷利康公司 狼瘡發作之治療
US20240327529A1 (en) 2020-11-18 2024-10-03 Astrazeneca Ab Steroid sparing
LT4114465T (lt) 2021-04-23 2023-11-10 Astrazeneca Ab Anti-ifnar1 dozavimo režimas, skirtas poodinei injekcijai
US20250002590A1 (en) 2021-04-23 2025-01-02 Astrazeneca Ab Treatment of lupus nephritis with anti-type i inf receptor antibody anifrolumab
CN113278070B (zh) 2021-04-25 2022-06-14 福州迈新生物技术开发有限公司 抗ck17蛋白单克隆抗体及其细胞株、制备方法和应用
CN113521276B (zh) * 2021-07-13 2022-04-12 江苏荃信生物医药股份有限公司 包含抗人干扰素α受体1(IFNAR1)单克隆抗体的液体制剂

Also Published As

Publication number Publication date
US20240360231A1 (en) 2024-10-31
CN120514844A (zh) 2025-08-22
CL2023003114A1 (es) 2024-04-19
US20220340669A1 (en) 2022-10-27
WO2022223714A1 (en) 2022-10-27
JP2024511227A (ja) 2024-03-12
US20230365698A1 (en) 2023-11-16
EP4306541A2 (en) 2024-01-17
CO2023015498A2 (es) 2023-11-30
SMT202300382T1 (it) 2024-01-10
BR112023021761A2 (pt) 2023-12-26
JP7484027B2 (ja) 2024-05-15
PT4114465T (pt) 2023-11-03
DK4114465T5 (da) 2024-07-22
HUE063562T2 (hu) 2024-01-28
AU2022260531B2 (en) 2024-03-07
AU2022260531A1 (en) 2023-11-30
PL4114465T3 (pl) 2024-04-08
AU2022260531A9 (en) 2023-12-07
KR20230166134A (ko) 2023-12-06
JP2024102205A (ja) 2024-07-30
AU2024201743A1 (en) 2024-04-04
CN120392997A (zh) 2025-08-01
IL307748A (en) 2023-12-01
EP4114465A1 (en) 2023-01-11
TW202317182A (zh) 2023-05-01
HRP20231255T1 (hr) 2024-02-02
RS64821B1 (sr) 2023-12-29
US12060429B2 (en) 2024-08-13
LT4114465T (lt) 2023-11-10
ES2963757T3 (es) 2024-04-01
CA3216387A1 (en) 2022-10-27
FI4114465T3 (fi) 2023-10-31
SI4114465T1 (sl) 2023-11-30
KR20250092298A (ko) 2025-06-23
EP4306541A3 (en) 2024-03-27
DK4114465T3 (da) 2023-10-30
EP4114465B1 (en) 2023-08-30
US20240400699A1 (en) 2024-12-05

Similar Documents

Publication Publication Date Title
MX2023012465A (es) Regimen de dosificacion de anti-ifnar1 para inyeccion subcutanea.
EP4272818A3 (en) Thrombolytic agent for the treatment of thromboembolism
MX2017010858A (es) Composicion para el tratamiento de enfermedades relacionadas con la interleucina 6.
NZ777261A (en) Combination of dextromethorphan and bupropion for treating depression
FR3034993B1 (fr) Conditionnement unitaire, compositions et schemas therapeutiques pour l'administration de stimulateurs des voies de pro-resolution sur des surfaces keratiniques
MX368507B (es) Uso de un anticuerpo anti-pd-1 en combinación con un anticuerpo anti-ctla-4 en la manufactura de un medicamento para el tratamiento de cáncer.
SG10201811128RA (en) Ezh2 inhibitors for treating lymphoma
EA201070757A1 (ru) Режим дозирования инъекционных препаратов эфиров палиперидона длительного действия
MX2014002555A (es) Una composicion farmacéutica para tratar cáncer, que comprende un conjugado de interferón alfa.
PH12017501222A1 (en) Glucagon derivatives with improved stability
MX2020011817A (es) Metodos para tratar el linfoma.
PH12022551052A1 (en) Combination therapy comprising an alk2 inhibitor and a jak2 inhibitor
ZA202400851B (en) Dosing regimens associated with extended release paliperidone injectable formulations
MX2024009188A (es) Regimenes de dosificacion asociados con formulaciones inyectables de paliperidona de liberacion prolongada.
AU2018282105A1 (en) Dosing of vibegron for treatment of overactive bladder
PH12019502651A1 (en) Use of vibegron to treat overactive bladder
MX2024013184A (es) Metodos y composiciones para tratar apnea del sue?o
MX2023006368A (es) Regimenes de dosificacion asociados con formulaciones inyectables de paliperidona de liberacion prolongada.
MX2021007330A (es) Composiciones y métodos terapéuticos para tratar cáncer usando ácido 6, 8-bis-benciltio-octanoico y un inhibidor de autofagia.
EA202193276A1 (ru) Способы лечения холангиокарциномы
MX2025011417A (es) Programa de dosificacion de un inhibidor de her.2
MX2020007222A (es) Metodos para el tratamiento de afecciones inflamatorias de la piel.
MX2019010086A (es) Esquema de dosificacion para una combinacion de ceritinib y una molecula de anticuerpo anti-pd-1.
MX2018007377A (es) Composicion de acido hialuronico para inyecciones en el pene.
MA60621B1 (fr) Régime de dosage de l'anti-ifnar1 pour injection sous-cutanée